Management of ocular mucous membrane pemphigoid

Theresa J. Gan, Jennifer Thorne

Research output: Contribution to journalArticle

Abstract

Mucous membrane pemphigoid (MMP) is an immune-mediated systemic disease affecting the mucosa of the mouth, eyes, nasopharynx, GI tract, genitalia and skin. Chronic inflammation and subepithelial blisters of the mucosa result in progressive scarring. Ocular MMP is characterized by a chronic cicatrizing conjunctivitis, which leads to symblepharon, entropion, trichiasis, severe dry eye, cornea ulceration and potential blindness when untreated. One of the most effective treatments for ocular MMP is the combination therapy of cyclophosphamide (administered for 12-18 months) and oral corticosteroids (tapered over 3-4 months). This regimen has proven effective in controlling conjunctival inflammation, halting mucosal scarring and preventing potential vision loss, and is typically used for severe disease. Long-term drug-free remission is achievable in patients with this regimen. For all immunosuppressive medications, careful monitoring for drug-related side effects is crucial.

Original languageEnglish (US)
Pages (from-to)271-279
Number of pages9
JournalExpert Review of Ophthalmology
Volume7
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Bullous Pemphigoid
Mucous Membrane
Cicatrix
Trichiasis
Entropion
Inflammation
Conjunctivitis
Genitalia
Nasopharynx
Mouth Mucosa
Blindness
Blister
Immunosuppressive Agents
Drug-Related Side Effects and Adverse Reactions
Cornea
Cyclophosphamide
Gastrointestinal Tract
Adrenal Cortex Hormones
Skin
Therapeutics

Keywords

  • cicatricial pemphigoid
  • corticosteroids
  • cyclophosphamide
  • ocular mucous membrane pemphigoid

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this

Management of ocular mucous membrane pemphigoid. / Gan, Theresa J.; Thorne, Jennifer.

In: Expert Review of Ophthalmology, Vol. 7, No. 3, 06.2012, p. 271-279.

Research output: Contribution to journalArticle

@article{8f4a7d96a9a542c488dd5f5e53815cb9,
title = "Management of ocular mucous membrane pemphigoid",
abstract = "Mucous membrane pemphigoid (MMP) is an immune-mediated systemic disease affecting the mucosa of the mouth, eyes, nasopharynx, GI tract, genitalia and skin. Chronic inflammation and subepithelial blisters of the mucosa result in progressive scarring. Ocular MMP is characterized by a chronic cicatrizing conjunctivitis, which leads to symblepharon, entropion, trichiasis, severe dry eye, cornea ulceration and potential blindness when untreated. One of the most effective treatments for ocular MMP is the combination therapy of cyclophosphamide (administered for 12-18 months) and oral corticosteroids (tapered over 3-4 months). This regimen has proven effective in controlling conjunctival inflammation, halting mucosal scarring and preventing potential vision loss, and is typically used for severe disease. Long-term drug-free remission is achievable in patients with this regimen. For all immunosuppressive medications, careful monitoring for drug-related side effects is crucial.",
keywords = "cicatricial pemphigoid, corticosteroids, cyclophosphamide, ocular mucous membrane pemphigoid",
author = "Gan, {Theresa J.} and Jennifer Thorne",
year = "2012",
month = "6",
doi = "10.1586/eop.12.29",
language = "English (US)",
volume = "7",
pages = "271--279",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Management of ocular mucous membrane pemphigoid

AU - Gan, Theresa J.

AU - Thorne, Jennifer

PY - 2012/6

Y1 - 2012/6

N2 - Mucous membrane pemphigoid (MMP) is an immune-mediated systemic disease affecting the mucosa of the mouth, eyes, nasopharynx, GI tract, genitalia and skin. Chronic inflammation and subepithelial blisters of the mucosa result in progressive scarring. Ocular MMP is characterized by a chronic cicatrizing conjunctivitis, which leads to symblepharon, entropion, trichiasis, severe dry eye, cornea ulceration and potential blindness when untreated. One of the most effective treatments for ocular MMP is the combination therapy of cyclophosphamide (administered for 12-18 months) and oral corticosteroids (tapered over 3-4 months). This regimen has proven effective in controlling conjunctival inflammation, halting mucosal scarring and preventing potential vision loss, and is typically used for severe disease. Long-term drug-free remission is achievable in patients with this regimen. For all immunosuppressive medications, careful monitoring for drug-related side effects is crucial.

AB - Mucous membrane pemphigoid (MMP) is an immune-mediated systemic disease affecting the mucosa of the mouth, eyes, nasopharynx, GI tract, genitalia and skin. Chronic inflammation and subepithelial blisters of the mucosa result in progressive scarring. Ocular MMP is characterized by a chronic cicatrizing conjunctivitis, which leads to symblepharon, entropion, trichiasis, severe dry eye, cornea ulceration and potential blindness when untreated. One of the most effective treatments for ocular MMP is the combination therapy of cyclophosphamide (administered for 12-18 months) and oral corticosteroids (tapered over 3-4 months). This regimen has proven effective in controlling conjunctival inflammation, halting mucosal scarring and preventing potential vision loss, and is typically used for severe disease. Long-term drug-free remission is achievable in patients with this regimen. For all immunosuppressive medications, careful monitoring for drug-related side effects is crucial.

KW - cicatricial pemphigoid

KW - corticosteroids

KW - cyclophosphamide

KW - ocular mucous membrane pemphigoid

UR - http://www.scopus.com/inward/record.url?scp=84861725837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861725837&partnerID=8YFLogxK

U2 - 10.1586/eop.12.29

DO - 10.1586/eop.12.29

M3 - Article

AN - SCOPUS:84861725837

VL - 7

SP - 271

EP - 279

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 3

ER -